{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:00:20Z","timestamp":1791262820280,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"S3","license":[{"start":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T00:00:00Z","timestamp":1450310400000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Nursing Practice"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:p>Patients with chronic lymphocytic leukaemia (CLL) are typically diagnosed at an advanced age and may have multiple co\u2010existing conditions, augmenting the challenges of treating their CLL. Aggressive cytotoxic therapies are often poorly tolerated in this patient population.<\/jats:p><jats:p>Obinutuzumab is a glycoengineered type II anti\u2010CD20 monoclonal antibody indicated in combination with chlorambucil for previously untreated CLL. The approval of this drug was based on the pivotal CLL11 trial, which demonstrated longer progression\u2010free survival vs. rituximab\/chlorambucil and chlorambucil alone in patients with significant co\u2010existing medical conditions and\/or poor renal function. However, a higher risk of infusion\u2010related reactions (IRRs) was demonstrated with obinutuzumab\u2010based therapy.<\/jats:p><jats:p>We highlight important nursing care considerations to help prevent and successfully manage IRRs and other important adverse events, to improve the treatment experience of patients receiving obinutuzumab infusions and to enable them to complete their treatment and receive optimal benefit. Premedication, drug handling, dosing, administration, monitoring and documentation are discussed.<\/jats:p>","DOI":"10.1111\/ijn.12412","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T07:20:53Z","timestamp":1450423253000},"page":"15-27","source":"Crossref","is-referenced-by-count":9,"title":["Prevention and management of obinutuzumab\u2010associated toxicities: Australian experience"],"prefix":"10.1111","volume":"21","author":[{"given":"Alicia","family":"Snowden","sequence":"first","affiliation":[{"name":"Peter MacCallum Cancer Centre  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Hayden","sequence":"additional","affiliation":[{"name":"St John of God Subiaco Hospital  Perth Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Dixon","sequence":"additional","affiliation":[{"name":"Roche Products Pty. Ltd, Dee Why  NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Gregory","sequence":"additional","affiliation":[{"name":"Monash Haematology, Monash Health  Clayton Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,12,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0104-4230(11)70019-7"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1992.tb24651.x"},{"key":"e_1_2_6_4_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)\u00ae. Non\u2010Hodgkin's lymphomas. Version 4.2014. Accessed August 2015."},{"key":"e_1_2_6_5_1","unstructured":"National Cancer Institute.Surveillance Epidemiology and End Results (SEER) database. SEER cancer statistics review 1975\u20132010. Available at:http:\/\/seer.cancer.gov\/. Accessed July 2015."},{"key":"e_1_2_6_6_1","unstructured":"Australian Institute of Health and Welfare (AIHW).Australian Cancer Incidence and Mortality (ACIM) book for chronic lymphocytic leukaemia. Available at:www.aihw.gov.au\/WorkArea\/DownloadAsset.aspx?id=60129546393. Accessed July 2015."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60456-0"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-206185"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701724785"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2008.01935.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.5646"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/11587650-000000000-00000"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.10.127"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_2_6_17_1","unstructured":"Roche Products Pty Limited.GAZYVA\u00ae Prescribing Information. Available at:www.roche\u2010australia.com\/productinfo\/gazyva. Version updated 28 April 2015."},{"key":"e_1_2_6_18_1","unstructured":"Roche Products Pty Limited Australia.MABTHERA\u00ae Australian approved Product Information. Available at:http:\/\/www.roche\u2010australia.com\/home\/products\/pharmaceuticals\/mabthera.html. Version updated 9 January 2015."},{"key":"e_1_2_6_19_1","unstructured":"Novartis Pharmaceuticals Australia Pty Limited.ARZERRA\u00ae Concentrated Injection. Product Information. Last updated 9 September 2011."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000381524"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"e_1_2_6_22_1","unstructured":"Therapeutic Goods Administration.Australian Public Assessment Report for obinutuzumab. PM\u20102013\u201001148\u20101\u20104 Final August 2014. Accessed August 2015."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.14"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1188\/10.CJON.E10-E21"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13403"},{"key":"e_1_2_6_26_1","doi-asserted-by":"crossref","unstructured":"BoschF IllmerT TurgutM et al.Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed\/Refractory Chronic Lymphocytic Leukemia (CLL). Abstract no. 3345. Paper presented at: American Society of Hematology (ASH) Annual Meeting and Exposition; December 6\u20139 2014; San Francisco CA.","DOI":"10.1182\/blood.V124.21.3345.3345"},{"key":"e_1_2_6_27_1","unstructured":"Roche Products PtyLimited.GAZYVA\u00ae (obiutuzumab). Consumer Medicine Information.http:\/\/www.guildlink.com.au\/gc\/ws\/ro\/cmi.cfm?product=rocgazyv10515.Version last updated 14 May 2015."},{"key":"e_1_2_6_28_1","unstructured":"La CasceAS CastellsMC BursteinH MeyerhardtJA.Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy. Available at:http:\/\/www.uptodate.com\/. Accessed August 2015."},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-601"},{"key":"e_1_2_6_30_1","first-page":"458","article-title":"Hypersensitivity reactions","volume":"19","author":"Weiss RB","year":"1992","journal-title":"Seminar in Oncology"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","unstructured":"FreemanC DixonM HoughtonR et al.Risk factors associated with the development of infusion\u2010related reactions in patients with chronic lymphocytic leukemia treated with anti\u2010CD20 monoclonal antibodies: Analysis of the CLL11 Study dataset. Abstract presented at ASH.;2014.","DOI":"10.1182\/blood.V124.21.3339.3339"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12327"},{"key":"e_1_2_6_33_1","unstructured":"Data on File. F. Hoffmann\u2010La Roche.Primary Clinical Study Report \u2010 BO 2 1004\/CLL11 \u2010 Stage 2."}],"container-title":["International Journal of Nursing Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijn.12412","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijn.12412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T23:21:11Z","timestamp":1694647271000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijn.12412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":32,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1111\/ijn.12412"],"URL":"https:\/\/doi.org\/10.1111\/ijn.12412","archive":["Portico"],"relation":{},"ISSN":["1322-7114","1440-172X"],"issn-type":[{"value":"1322-7114","type":"print"},{"value":"1440-172X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]}}}